ASCO 2021 | Final OS from NETTER-1: lutetium-177-DOTATATE in patients with midgut NETs

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the final overall survival results of NETTER-1 (NCT01578239), a Phase III study evaluating lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors (NETs). With a median follow-up of 6.3 years, overall survival (OS), a secondary endpoint, in the intention to treat population did not reach statistical significance. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.